Ravneet Vohra1, Guy Odom2, Jeffrey S Chamberlain2,3,4, and Donghoon Lee1
1Radiology, University of Washington, Seattle, WA, United States, 2Neurology, University of Washington, Seattle, WA, United States, 3Medicine, University of Washington, Seattle, WA, United States, 4Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, WA, United States
1Radiology, University of Washington, Seattle, WA, United States, 2Neurology, University of Washington, Seattle, WA, United States, 3Medicine, University of Washington, Seattle, WA, United States, 4Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, WA, United States
AAV-μDys administration
ameliorates skeletal phenotype of mdx4cv mice.
Figure 2: 31P metabolites
demonstrate significant differences between groups. PCr, a and b-ATP
levels improved with AAV-μDys treatment.
Figure 1: Multiparametric measures T2, T1, and
MTR % demonstrate AAV-mDys treatment
effects in mdx4cv mice.
